Serum myeloperoxidase, paraoxonase, and plasma asprosin concentrations in patients with acute myocardial infarction

• Published in: Heliyon 2024-04, Vol.10 (8), p.e29465-e29465, Article e29465
• Main Authors: Ciftci, Handan, Gul, Huseyin Fatih, Sahin, Levent, Dolanbay, Turgut, Canacik, Omer, Karsli, Emre, Ercin, Dogan, Karapehlivan, Mahmut
• Format: Article
• Language: English
• Subjects: Acute myocardial infarction; Asprosin; Hs-cTnI; Myeloperoxidase; Paraoxonase
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e29465

The objective of this study was to evaluate the usefulness of the serum biomarkers myeloperoxidase (MPO), paraoxonase (PON), and plasma asprosin in acute myocardial infarction (AMI) diagnosis and assess their compatibility with routinely screened cardiac biomarkers. This study was conducted using a prospective cross-sectional design and included 90 patients, consisting of 60 patients diagnosed with AMI (30 with ST-segment elevation and 30 with non-ST-segment elevation on ECG) and 30 controls (without a diagnosis of AMI). Changes in the levels of cardiac biomarkers (Hs-cTnI, CK, CK-MB), lipid profile (TC, TG, LDL, HDL), MPO, PON, asprosin, and routine biochemical parameters of patients were evaluated. Furthermore, receiver operating characteristic curve analysis revealed the diagnostic value of Hs-cTnI, MPO, PON, and asprosin in predicting AMI. Binary logistic regression analysis of cardiac marker concentrations was used to predict the presence of AMI. In contrast, multinomial logistic regression analysis was conducted to predict the type of AMI and the control group. The median levels of MPO and plasma asprosin were found to be higher in the patient group (3.22 [interquartile range {IQR}: 2.4–4.4] ng/ml and 10.84 [IQR: 8.8–17.8] ng/ml, respectively) than in the control group (2.49 [IQR: 1.9–2.9] ng/ml and 4.82 [IQR: 4.6–8.0] ng/ml, respectively) (p = 0.001 and p